SELECT Trial: Semaglutide Cut Major Cardiovascular Events by 20% in Adults Without Diabetes

What the SELECT Trial Was and Why It Was Designed

SELECT was a double-blind, randomized, placebo-controlled outcomes trial that ran from October 2018 through June 2023. The question it asked was specific: does semaglutide 2.4 mg reduce MACE in people who are overweight or obese, have established atherosclerotic cardiovascular disease, but have never been diagnosed with type 2 diabetes? That last clause mattered. Every major GLP-1 cardiovascular outcomes trial before SELECT, including LEADER (liraglutide) and SUSTAIN-6 (semaglutide 0.5/1 mg), enrolled patients with type 2 diabetes. SELECT was the first large-scale cardiovascular outcomes trial to test a GLP-1 receptor agonist in a non-diabetic population at high cardiac risk.

Eligibility required age 45 or older, BMI of 27 or above, and documented CVD (prior myocardial infarction, stroke, or symptomatic peripheral artery disease). Patients with a current or prior diagnosis of type 2 diabetes were excluded. The 17,604 participants were randomized 1:1 to weekly subcutaneous semaglutide 2.4 mg or matched placebo, titrated over 16 weeks to the full dose per the standard Wegovy escalation schedule [1].

The primary endpoint was time to first occurrence of cardiovascular death, nonfatal MI, or nonfatal stroke. The trial was event-driven, requiring at least 1,225 adjudicated MACE events to achieve the pre-specified 80% power for a hazard ratio of 0.84.

Primary MACE Result: 20% Relative Risk Reduction

The headline number is clean. Semaglutide reduced the composite MACE endpoint by 20% versus placebo (HR 0.80; 95% CI 0.72, 0.90; P<0.001) [1]. MACE occurred in 6.5% of the semaglutide group versus 8.0% of the placebo group across the median 39.8-month follow-up. That absolute risk reduction of 1.5 percentage points translates to a number needed to treat of approximately 67 patients over roughly three years to prevent one MACE event.

Breaking down the composite: nonfatal MI drove much of the effect (HR 0.72; 95% CI 0.61, 0.85). Cardiovascular death trended in the same direction (HR 0.85; 95% CI 0.71, 1.01), though that component did not cross the conventional significance threshold on its own. Nonfatal stroke showed a directionally consistent reduction (HR 0.93; 95% CI 0.74, 1.15) that was not individually significant, which the authors attributed to lower statistical power for that endpoint alone.

The trial publication, led by A. Michael Lincoff, MD, stated: "Semaglutide at a dose of 2.4 mg per week was superior to placebo in reducing the incidence of cardiovascular death, nonfatal myocardial infarction, or nonfatal stroke among patients with preexisting cardiovascular disease and overweight or obesity without diabetes." [1]

That sentence carries weight. The benefit appeared durable. The Kaplan-Meier curves separated within the first six months and continued to diverge through month 40, suggesting an effect that accumulates rather than plateaus.

Was the Benefit From Weight Loss or a Direct Drug Effect?

This is the most debated mechanistic question in the SELECT data. The mean body weight reduction in the semaglutide arm was 9.4% at 104 weeks versus 0.9% in the placebo arm. Critics and proponents alike ask: is the cardiovascular benefit simply a downstream result of losing roughly 10% body weight, or does semaglutide act on the vasculature and myocardium directly?

The SELECT authors conducted exploratory mediation analyses. Weight loss accounted for a minority of the observed risk reduction. Anti-inflammatory effects, blood pressure reductions (systolic BP fell approximately 3.3 mmHg more in the semaglutide arm), and favorable lipid shifts all contributed. Waist circumference dropped 7.7 cm with semaglutide versus 1.3 cm with placebo, and hsCRP, a marker of systemic inflammation, fell meaningfully in the semaglutide group.

GLP-1 receptors are expressed in cardiac and vascular tissue [2], and animal studies have long suggested direct myocardial protection. SELECT cannot isolate these mechanisms in humans, but the mediation data make it unlikely that weight loss alone explains a 20% MACE reduction when the absolute weight difference between groups was roughly 8 to 9 kg.

Who Qualifies: The SELECT Population Profile

The enrolled population was predominantly male (72%), white (77%), and had a mean age of 61.6 years. Mean BMI at baseline was 33.3 kg/m2. All participants had at least one qualifying CVD event: prior MI (72%), prior stroke (23%), or symptomatic peripheral artery disease (12%). Baseline HbA1c was below 6.5% for all participants, confirming no diabetes at entry.

Patients with eGFR <15 mL/min/1.73m2 or active cancer were excluded. Personal or family history of multiple endocrine neoplasia type 2 (MEN2) or medullary thyroid carcinoma remained an absolute contraindication, consistent with the existing Wegovy label [3].

The FDA updated the Wegovy prescribing label in 2024 to include a cardiovascular risk reduction indication specifically matching the SELECT population: adults with BMI ≥27 and established CVD [3]. That label update means a clinician can now prescribe Wegovy for cardiac risk reduction as a standalone indication, separate from the weight management label.

How SELECT Compares to the STEP Trials

SELECT addressed cardiovascular outcomes. The STEP program addressed weight reduction. Both use semaglutide 2.4 mg weekly but answer entirely different questions, and conflating their results leads to prescribing confusion.

STEP-1 (N=1,961, non-diabetic adults): Semaglutide 2.4 mg produced 14.9% mean body weight loss at 68 weeks versus 2.4% with placebo. Roughly 86% of participants lost at least 5% body weight [4]. This remains the benchmark efficacy figure for non-diabetic weight loss.

STEP-2 (N=1,210, adults with type 2 diabetes): Mean weight loss was 9.6% with semaglutide 2.4 mg versus 3.4% placebo at 68 weeks, with HbA1c falling 1.6 percentage points in the semaglutide group [5]. The attenuated weight loss compared to STEP-1 is consistent with the known effect of antidiabetic medications and altered GLP-1 receptor sensitivity in T2D.

STEP-3 (N=611, semaglutide plus intensive behavioral therapy): Adding a 30-session intensive behavioral intervention to semaglutide 2.4 mg produced 16.0% mean weight loss at 68 weeks versus 5.7% with placebo plus behavioral therapy [6]. The behavioral therapy arm amplified weight loss, pointing to the additive value of structured lifestyle support.

STEP-5 (N=304, 104-week extension): At two full years, semaglutide 2.4 mg maintained 15.2% mean body weight reduction versus 2.6% placebo [7]. This is the longest duration randomized controlled trial data for semaglutide weight loss and directly informs the clinical question of how long the benefit persists during continuous treatment.

The STEP program collectively established the weight loss efficacy profile. SELECT took that same drug dose and answered whether the drug reduces hard cardiovascular events. Together, they describe a compound that does both.

The table below summarizes the key parameters across trials to help clinicians match the right evidence base to the right patient:

| Trial | N | Population | Duration | Primary Result | |---|---|---|---|---| | STEP-1 | 1,961 | Obesity, no T2D | 68 wks | 14.9% weight loss | | STEP-2 | 1,210 | Obesity + T2D | 68 wks | 9.6% weight loss | | STEP-3 | 611 | Obesity + behavioral therapy | 68 wks | 16.0% weight loss | | STEP-5 | 304 | Obesity, no T2D | 104 wks | 15.2% weight loss | | SELECT | 17,604 | Overweight/obesity + CVD, no T2D | 39.8 mo | 20% MACE reduction |

Safety Profile in SELECT: What 17,604 Patients Showed

The adverse event profile in SELECT was consistent with the known GLP-1 class profile but with a large enough sample to quantify rates precisely. Gastrointestinal events were the most common reason for discontinuation: nausea occurred in 19.3% of the semaglutide group versus 11.6% placebo; diarrhea in 16.6% versus 10.7%; and vomiting in 10.6% versus 5.4% [1]. These rates closely mirror what STEP-1 reported in a shorter 68-week window.

Serious adverse events occurred in 33.4% of the semaglutide group versus 36.4% placebo, meaning the drug arm had fewer serious events numerically, driven largely by the reduction in MACE.

Gallbladder disease was elevated: cholelithiasis occurred in 2.8% semaglutide versus 2.3% placebo. Acute pancreatitis was infrequent in both arms (0.3% vs. 0.2%). Diabetic retinopathy complications, a signal seen in prior SUSTAIN trials in diabetic patients, were not a safety concern in the non-diabetic SELECT population, occurring at 0.7% in both arms.

Discontinuation due to adverse events ran at 16.6% for semaglutide versus 8.2% for placebo across the trial duration, a meaningful gap that is relevant for counseling patients on long-term adherence. The AACE Clinical Practice Guidelines for comprehensive medical care in obesity recommend that providers discuss the GI side-effect trajectory with patients before starting GLP-1 therapy, noting that nausea typically peaks in the first 4 to 8 weeks and then attenuates [8].

Comparing SELECT to LEADER and SUSTAIN-6

Before SELECT, the cardiovascular evidence for GLP-1 agonists came from diabetic populations. LEADER (N=9,340) showed liraglutide 1.8 mg reduced MACE by 13% (HR 0.87; 95% CI 0.78, 0.97) in patients with T2D and high CV risk [2]. SUSTAIN-6 (N=3,297) showed semaglutide 0.5/1 mg reduced MACE by 26% (HR 0.74; 95% CI 0.58, 0.95) in T2D patients over 104 weeks, though SUSTAIN-6 was powered for non-inferiority rather than superiority.

SELECT extended this evidence base to people without diabetes for the first time. That the relative risk reduction (20%) was similar in magnitude to LEADER in a non-diabetic population suggests the cardiovascular benefit is not primarily mediated through glycemic improvement. Glucose-lowering contributed zero to the SELECT result because participants did not have diabetes to begin with.

Implications for Prescribing Semaglutide 2.4 mg Today

The 2024 Wegovy label change creates a distinct prescribing pathway. A patient with BMI ≥27, prior MI or stroke, and no diabetes now has a labeled cardiovascular indication for semaglutide 2.4 mg, independent of whether weight loss is the clinical goal [3]. Cardiologists, not just obesity medicine specialists or endocrinologists, are now appropriate prescribers for this indication.

For patients with both T2D and established CVD, the decision tree involves comparing semaglutide 2.4 mg (Wegovy) against semaglutide 1 mg (Ozempic) and against SGLT-2 inhibitors like empagliflozin or dapagliflozin, each of which also carries cardiovascular outcome trial data in diabetic populations. The SELECT population excluded T2D, so direct extrapolation to that group requires clinical judgment.

Tirzepatide (Zepbound, Mounjaro) has not yet reported a dedicated cardiovascular outcomes trial. SURMOUNT-1 (N=2,539) demonstrated up to 22.5% mean weight loss with tirzepatide 15 mg at 72 weeks [9], and SURMOUNT-2 showed 15.7% weight loss in patients with T2D at 72 weeks [10], but neither trial used MACE as a primary endpoint. The SURPASS-CVOT trial for tirzepatide is ongoing.

Dose escalation for Wegovy follows the labeled 16-week titration: 0.25 mg weekly for weeks 1 to 4 to 0.5 mg for weeks 5 to 8 to 1.0 mg for weeks 9 to 12 to 1.7 mg for weeks 13 to 16, then 2.4 mg from week 17 onward [3]. Patients who cannot tolerate the 2.4 mg dose may remain at 1.7 mg per the label.

Any patient with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome must not receive semaglutide in any form. Active or recent pancreatitis is also a contraindication. Clinicians should review the current Wegovy prescribing information before initiating therapy [3].

What SELECT Did Not Show

Honest evaluation of SELECT requires acknowledging its limits. The trial enrolled 72% male participants, which limits direct applicability to women, though subgroup analyses showed directionally consistent results across sexes. The population was also 77% white, which underrepresents the groups carrying disproportionate obesity and cardiovascular burden in the United States.

The trial did not show a statistically significant reduction in cardiovascular death on its own, only in the composite MACE endpoint. All-cause mortality was 4.3% versus 4.8% (HR 0.81; 95% CI 0.71, 0.93 for expanded MACE including hospitalization for heart failure and coronary revascularization, per secondary endpoint data), but the pre-specified primary endpoint was the three-component composite.

SELECT also did not randomize patients to different doses. The 2.4 mg dose is the only one studied for the cardiovascular indication. Whether the 0.5 mg or 1.0 mg semaglutide doses used in glycemic management would produce similar MACE reductions remains unknown from this dataset.

Integrating SELECT Into a Treatment Decision for a Real Patient

Consider a 58-year-old man, BMI 31, prior MI two years ago, HbA1c 5.9%, on a statin and aspirin, referred for cardiovascular risk reduction. He meets the SELECT population criteria exactly. Under the 2024 Wegovy label, semaglutide 2.4 mg is indicated for him as a cardiovascular risk-reduction agent. Based on SELECT data, his expected absolute risk reduction for a MACE event is approximately 1.5 percentage points over three years. He may also lose 9 to 15% of his body weight based on STEP-1 and SELECT weight data.

Counsel him that nausea is likely during titration, peaks around weeks 4 to 8, and resolves in most patients. Set an appointment at week 16 to confirm tolerance of the full 2.4 mg dose. If he develops symptomatic cholelithiasis (a 0.5% absolute excess risk over placebo in SELECT), hold the medication and evaluate. Monitor HbA1c annually; some patients on semaglutide will see their prediabetes improve, which is itself a metabolic benefit, though not a SELECT-defined endpoint.

In the SELECT trial, the cardiovascular benefit was consistent across subgroups stratified by BMI, sex, age, region, and baseline lipid levels. A patient does not need to achieve maximal weight loss for the drug to reduce cardiovascular risk. The curves in SELECT separated early and remained separated whether or not patients achieved 5% weight loss.

The Endocrine Society notes in its 2023 clinical practice guidance that GLP-1 receptor agonists with proven cardiovascular benefit should be prioritized in patients with established CVD who have overweight or obesity, regardless of glycemic status. That language maps directly onto the SELECT result and the updated Wegovy indication [11].